Society of Hematologic Oncology Insider news
Society of Hematologic Oncology Insider news
Podcast Description
SOHO Insider delivers on the latest news in hematologic oncology and updates from the Society of Hematologic Oncology
Podcast Insights
Content Themes
The podcast mainly covers advancements in hematologic oncology, including FDA approvals, treatment strategies, and emerging therapies. For example, episodes have explored the journey of belantamab mafodotin for multiple myeloma, challenges in treating TP53-mutated acute myeloid leukemia, and target treatment goals in myeloproliferative neoplasms. It emphasizes practical insights from clinical trials and their impact on patient care.
SOHO Insider delivers on the latest news in hematologic oncology and updates from the Society of Hematologic Oncology
In this SOHO Insider podcast, host Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, spoke with Roberto Mina, MD, associate professor of hematology at Emory University, on news from the 2026 ASCO Annual Meeting.
The conversation highlighted a presentation by Dr. Roberto Mina regarding the pivotal phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy for patients with relapsed/refractory multiple myeloma who were previously exposed to lenalidomide and anti-CD38 antibodies
Follow more news from ASCO here.
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.